News About: Pharm. Industry
GSK registered the most patents last year
It is known that the number of cases registered in the Green List (a catalogue for pharmaceutical product patents) were 182 in the last year and 1618 in total.
The company with the most registered patents was turned ...
BMS won the nullity trial for the Baraclude’s patent
BMS Pharmaceutical Korea announced on the 13th that it won a nullity trial for the substance patent of the hepatitis type B treatment ‘Baraclude (generic name: entecavir)’.
Eun-young Kim, CEO of BMS Pharmaceutical Ko...
Top listed pharmaceutical companies have engaged in the ‘speed battle’over the next generation antiulcer drug
CJ Healthcare, Yuhan Corporation and Dawwoong Pharmaceutical are engaged in a speed battle over the P-CAB-type (Potassium Competitive Acid Blocker) drug, receivingattention as the next generation antiulcer drug.
The ...
Brilinta has been approved to crush to administer for the first time as an antiplatelet drug
The AstraZeneca’s ‘Brilinta (generic name: ticagrelor)’ has been approved to administer in a crushed form by the Ministry of Food andDrug Safety for the first time as an antiplatelet drug.
It is observed that the app...
The COX-2 inhibitor market has gotten heated up with launched of generics and new drugs
Pfizer has made movements to prevent the ‘Sales Cliff’ phenomenon in which sales decline after the patent expiration of the selective COX-2 inhibitor ‘Celebrex (generic name: celecoxib)’ that will be expired in June t...
Pfizer Korea and Jaeil Pharmaceutical has made the joint promotion agreement for ‘Celebrex’
Pfizer Korea (CEO Dong-soo Lee) and Jaeil Pharmaceutical (CEO Suk-jae Sung) held the joint promotion agreement ceremony andstrategy workshop for‘Celebrex (generic name: celecoxib)’ on the last 9th.
Under the joint pr...
What are the blockbuster-level generics in 2015?
As a series of blockbuster-level pharmaceutical products is about to be expired this year, competitions between‘keepers (pharmaceutical companies)’ and ‘getters(pharmaceutical companies)’ will get even fiercer.
Pharm...
Would it different from Vioxx? The challenge of the COX-2 inhibitor, Arcoxia, will beginMSD has challenged the COX-2 inhibitor market again. However, it is analyzed that the expected result for the new challenge would not be different from the old one.
The Ministr...
|
“The Chinese unethical business custom will be an obstacle of entry for domestic pharmaceutical companies”
It is analyzed that unethical business customs in the pharmaceutical industry in China would be amajor obstacle for domestic pharmaceutical companies to enter in the non-tariff field.
Since many multinational pharmac...
Domestic pharmaceutical companies have failed on the patent nullity of Baraclude
As Daewoong Pharmaceutical and Hanmi Pharmaceutical have failed on the substance patent nullity of Baraclude, domestic pharmaceutical companies’ exclusive sale rights have also been blown away, too.
If the substance ...
